INTRODUCING ELEUSIS AS A SILVER PARTNER FOR PSYCH

Eleusis was founded in 2013 as the world’s first company dedicated to the transformation of psychedelics into medicines. The company was co-founded by Shlomi Raz, and Charles Nichols, a current professor of pharmacology and experimental therapeutics at Louisiana State University.

The clinical-stage life sciences company aims to develop an innovative platform of drug discovery and care delivery solutions, rooted in psychedelic medicine, which will enable the formulation of urgently needed therapeutic alternatives for treating inflammatory disease and mental health disorders.

“Eleusis has the unprecedented opportunity to address a broad spectrum of urgent, unmet needs through unlocking both the anti-inflammatory potential of psychedelics and their safe-use within psychiatry.” — Shlomi Raz, CEO and Chairman of Eleusis.

The company’s collective IP portfolio, scientific and clinical research expertise, and advanced commercial development enable Eleusis to pursue two significant opportunities via separate and wholly owned subsidiaries:

1. Eleusis Therapeutics – realizing the anti-inflammatory potential of psychedelics

2. Eleusis Health Solutions – enabling broad access to safe, effective, and cost-efficient psychoactive drug therapy

Eleusis will be joining Prohibition Partners LIVE to share insights accumulated over years of drug discovery research and study of psychedelics as therapeutic medicines.

Join Prohibition Partners LIVE on 22 – 23 June to discover the latest developments in the European cannabis sector, learn from our world-renowned speakers, and engage with our network of industry-leading professionals who are pushing boundaries in the cannabis space.